Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis
| Autor: | Ru Chong Chen, Hong Shan, Yu Hu, Shi Yue Li, Chun Li Tang, Jianfu Li, Feng Ye, Jie Xiang, Ya Hua Hu, Li Min Ou, Wei Wang, Shan Xiong, Yi Xiang Peng, Zheng Yi Ni, Li Li, Wei Jie Guan, Jianxing He, Shao Qin Qiu, Zhong Chen, Yimin Li, Lin Ling Cheng, Heng Rui Liang, Tao Wang, Wenhua Liang, Yi Zhao, Xiaoqing Liu, Chun Liang Lei, Zi Sheng Chen, Li Wei, Nanshan Zhong, Ling Sang, Chang Jiang Ye, Bo Cheng, Zhi Jian Zheng, Jin Ping Zheng, Nuo Fu Zhang, Yong Liu, Shao Yong Zhu, Caichen Li, Chun-Quan Ou, Jie Luo, Ping Yan Chen, Jian-ming Wang, Ji Yang Liu, Lei Liu, Peng Peng, Gang Li |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Adult Male medicine.medical_specialty China Pneumonia Viral Comorbidity Malignancy law.invention 03 medical and health sciences Betacoronavirus 0302 clinical medicine law Risk Factors Internal medicine Diabetes mellitus medicine Humans 030212 general & internal medicine Pandemics COPD business.industry SARS-CoV-2 Hazard ratio COVID-19 Middle Aged medicine.disease Prognosis Intensive care unit Confidence interval 030104 developmental biology Population study Female business Coronavirus Infections Concise Research Report |
| Zdroj: | European respiratory journal, Early view Journal of General Internal Medicine European respiratory journal, 55:2000547 |
| Popis: | BackgroundThe coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide.ObjectiveTo evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status.MethodsWe analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities.ResultsThe mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities.ConclusionAmong laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|